A small randomized clinical trials showed that, liraglutide (3 mg daily) administration for 26 weeks reduced serum ALT and AST on obese NAFLD subjects without T2DM. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.